Stockscreener 앱 받기
2.78
6.51%
0.17
시간 외 거래:
2.82
0.04
+1.44%
전일 마감가:
$2.61
열려 있는:
$2.64
하루 거래량:
3.27M
Relative Volume:
1.25
시가총액:
$342.01M
수익:
$34.86M
순이익/손실:
$-103.80M
주가수익비율:
-2.3472
EPS:
-1.1844
순현금흐름:
$-96.02M
1주 성능:
-2.46%
1개월 성능:
-18.95%
6개월 성능:
-3.81%
1년 성능:
+25.23%
1일 변동 폭
$2.60
$2.846
1주일 범위
$2.59
$3.30
52주 변동 폭
$1.6901
$5.17
Ccc Intelligent Solutions Holdings Inc Stock (CCCC) Company Profile
명칭
Ccc Intelligent Solutions Holdings Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
Ccc Intelligent Solutions Holdings Inc
|
2.78 | 342.01M | 34.86M | -103.80M | -96.02M | -1.1844 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ccc Intelligent Solutions Holdings Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-09 | 개시 | JP Morgan | Overweight |
| 2025-12-02 | 개시 | TD Cowen | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
Ccc Intelligent Solutions Holdings Inc 주식(CCCC)의 최신 뉴스
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
C4 Therapeutics Director Donna Roy Grogan Receives 4,618 Shares Instead of Cash Compensation - Kalkine Media
Shares replace cash pay as C4 Therapeutics (CCCC) director receives 3,662 shares. - Stock Titan
Director receives 4,618 shares instead of cash compensation at C4 Therapeutics (CCCC) - Stock Titan
C4 Therapeutics Inc (CCCC-Q) Stock Price and News - The Globe and Mail
Form 4 C4 Therapeutics Inc For: 27 September By Investing.com - Investing.com Nigeria
Form 4 C4 Therapeutics Inc For: 27 September By Investing.com - Investing.com India
Form 8K C4 Therapeutics Inc For: 25 September By Investing.com - Investing.com Canada
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society Annual Meeting - Investing News Network
C4 Therapeutics presents cemsidomide trial biomarker data - Investing.com
C4 Therapeutics Reports Phase 1 Cemsidomide Biomarker Data Showing T-Cell Activation and Advances Elranatamab Combination Trial - Quiver Quantitative
C4 Therapeutics: 53% of 20 respond at trial dose - Stock Titan
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting - GlobeNewswire Inc.
In two patients with blood cancer, tests suggest a drug combo may keep immune cells from wearing out. - Stock Titan
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
C4 Therapeutics (NASDAQ: CCCC) CFO logs RSU shares, withholds stock for taxes - Stock Titan
C4 Therapeutics (Nasdaq:CCCC)Stock Analysis - Simply Wall Street
CCC Intelligent Solutions Holdings Inc. Common Stock $CCC Shares Sold by Amundi - MarketBeat
Copart to buy ACV Auctions in $1.9 billion deal - Reuters
Copart earnings up next amid CCC deal talks, growth strategy test - investing.com
CCC Intelligent Solutions Holdings Inc. (CCC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Eastern Progress
Wellington Management Group LLP Invests $17.87 Million in CCC Intelligent Solutions Holdings Inc. Common Stock $CCC - MarketBeat
C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts (NASDAQ:CCCC) - Seeking Alpha
CCC Intelligent Solutions Holdings Inc. Common Stock $CCC Shares Purchased by Ancora Advisors LLC - MarketBeat
Susquehanna Fundamental Investments LLC Cuts Holdings in CCC Intelligent Solutions Holdings Inc. Common Stock $CCC - MarketBeat
CCC Intelligent Solutions Holdings Inc. Common Stock $CCC Shares Purchased by Thornburg Investment Management Inc. - MarketBeat
Could Copart (CPRT) Stock Gain from a Transformative Deal for CCC Intelligent Solutions (CCC)? - Yahoo Finance
CCC on reported talks of selling company - repairerdrivennews.com
Analysts Offer Insights on Technology Companies: CCC Intelligent Solutions Holdings (CCC) and Lsi Industries (LYTS) - The Globe and Mail
CCC Intelligent Solutions Holdings Inc. Common Stock (NASDAQ:CCC) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Analysts Offer Insights on Technology Companies: nCino (NCNO), Salesforce (CRM) and Hon Hai Precision Industry (OtherHNHPF) - The Globe and Mail
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Car-Seller Copart Is Among Suitors for Software Firm CCC - Yahoo Finance
CCC (CCC) Today: Finishes 3.78% Higher at $7.41; Market Levels: Price Remains Between $7.04 Support and $7.78 Resistance for the Current SessionCall Spread Alert - Vinanet
Copart Reportedly In Talks To Acquire CCC Intelligent Solutions - Auto Recycling World
Car-Seller Copart Among Suitors for Car Insurance Software Firm CCC - Claims Journal
Watch Car-Seller Copart Is Among Suitors for Software Firm CCC - Bloomberg.com
Why CCC Intelligent Solutions Stock Rose Today - Moomoo
Why CCC Intelligent Solutions Stock Rose Today - Quiver Quantitative
Longtime Chicago auto tech firm CCC draws takeover interest - Crain's Chicago Business
CCC Intelligent Solutions gains on report of Copart takeover talks - Seeking Alpha
Car-Seller Copart Is Among Suitors for Car Insurance Software Firm CCC - Bloomberg.com
CCC Intelligent (NYSE: CCC) investor to sell 368,930 shares - Stock Titan
T. Rowe Price (CCC) discloses 7.5% beneficial stake in CCC Intelligent Solutions - Stock Titan
RA Capital discloses 9.99% C4 Therapeutics (CCCC) stake with warrant blockers - Stock Titan
CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC) - intelligentinvestor.com.au
Is VRSK Worth Buying as Recurring Revenue Battles a Premium Valuation? - TradingView
Verisk's AI Expansion Gains Traction as Insurance Adoption Scales - tradingview.com
Crash Champions Empowers Team Members with AI and Tools from CCC - The Manila Times
Crash Champions Expands AI Use to Help Repair Teams Spend More Time - Stock Titan
Ccc Intelligent Solutions Holdings Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ccc Intelligent Solutions Holdings Inc 주식 (CCCC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| JAY GELDMACHER | Former REZI CEO |
Aug 14 '26 |
Proposed Sale |
23.01 |
82,563 |
1,899,926 |
0 |
| Mark Mossler | Officer |
Aug 13 '26 |
Proposed Sale |
4.07 |
15,000 |
61,072 |
0 |
| Mark Mossler | Officer |
Aug 12 '26 |
Proposed Sale |
3.93 |
19,519 |
76,680 |
0 |
| Anderson Kenneth Carl | Director |
Jun 01 '26 |
Option Exercise |
2.11 |
1,070 |
2,258 |
69,300 |
| Mark Mossler | Former Section 16 Officer |
May 27 '26 |
Proposed Sale |
3.91 |
9,087 |
35,485 |
0 |
| JOLIE M SIEGEL | Officer |
Mar 09 '26 |
Proposed Sale |
3.74 |
101,175 |
378,849 |
0 |
| REYNO LEONARD | Chief Medical Officer |
Jan 16 '26 |
Sale |
2.22 |
10,000 |
22,200 |
156,382 |
1.35%
자본화:
|
볼륨(24시간):